article 2024 DISPROPORTIONALITY ANALYSIS WITH COMPARISON OF ELAGOLIX VERSUS LEUPROLIDE SAFETY IN WOMEN WITH ENDOMETRIOSIS USING DATA FROM THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) ·doi:10.1016/j.fertnstert.2024.07.297